|
|
Volumn 25, Issue 19, 2006, Pages 3245-3249
|
|
FDA perspective on trials with interim efficacy evaluations
|
|
Author keywords
Adaptive; Early stopping; Enrichment
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
ANTIARRHYTHMIC AGENT;
ANTIDEPRESSANT AGENT;
ANTITHROMBOCYTIC AGENT;
GLYCERYL TRINITRATE;
NITRATE;
PLACEBO;
ALZHEIMER DISEASE;
ARTICLE;
BLEEDING;
CALCULATION;
CLINICAL TRIAL;
DEATH;
DOSE CALCULATION;
DOSE RESPONSE;
DRUG EFFICACY;
DRUG INFORMATION;
DRUG MARKETING;
DRUG MEGADOSE;
DRUG RESEARCH;
DRUG RESPONSE;
EXERCISE TOLERANCE;
FOOD AND DRUG ADMINISTRATION;
HEART DISEASE;
HEART VENTRICLE EXTRASYSTOLE;
HUMAN;
HYPOTENSION;
METHODOLOGY;
MULTIPLE DRUG DOSE;
PATIENT SELECTION;
RANDOMIZATION;
RESEARCH ETHICS;
RISK BENEFIT ANALYSIS;
SAMPLE SIZE;
SEQUENTIAL ANALYSIS;
STATISTICAL ANALYSIS;
STATISTICAL SIGNIFICANCE;
SURVIVAL;
SYSTEMATIC ERROR;
TRANSDERMAL PATCH;
TREATMENT OUTCOME;
CLINICAL TRIALS;
CLINICAL TRIALS AS TOPIC;
HUMANS;
MODELS, STATISTICAL;
SAMPLE SIZE;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 33749371301
PISSN: 02776715
EISSN: 10970258
Source Type: Journal
DOI: 10.1002/sim.2631 Document Type: Article |
|
Times cited : (13)
|
|
References (0)
|
